MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

JAK1 inhibition

  • Home
  • JAK1 inhibition
Ivarmacitinib 在掌跖脓疱病中展现快速且令人鼓舞的疗效与免疫调节作用：多中心临床试验启示
Posted inAllergy & Immunology Dermatology news

Ivarmacitinib Shows Promising Rapid Efficacy and Immune Modulation in Palmoplantar Pustulosis: Insights from a Multicenter Clinical Trial

Posted by By MedXY 10/25/2026
Ivarmacitinib, a selective JAK1 inhibitor, demonstrated rapid efficacy and immune remodeling in palmoplantar pustulosis over 12 weeks, with favorable safety and potential biomarkers for response stratification.
Read More
  • Enhancing Post-Stroke Physical Activity Through Telehealth and Wearable Technology: A Feasibility Randomised Controlled Trial
  • Advancing Dental Education: Repair Versus Replacement of Defective Composite Restorations in Canadian Dental Schools
  • Immunogenicity and Safety of Fractional 17DD Yellow Fever Vaccine Doses in Young Children: Evidence from a Phase 4 Randomised Trial in Uganda and Broader Context
  • Enhancing Prehospital Pediatric Ventilation Quality with Real-Time Feedback Devices: Insights from a Randomized Study
  • Nerandomilast Shows Promise in Slowing Progressive Pulmonary Fibrosis in Autoimmune Disease: Insights from the FIBRONEER-ILD Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top